SEPTIN9 and hepatocellular carcinoma: In 2018, in two phase 2 studies, the methylation of SEPT9 promoter in cfDNA was shown to offer high sensitivity (85–94%) and specificity (84–91%) in discriminating HCC cases among cirrhotic patients [39].